Cardio Diagnostics Holdings, Inc. cash flow to debt ratio of -823.27% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Cardio Diagnostics Holdings, Inc.'s free cash flow has decreased 9.58% from $-5.40M last year to $-5.91M, signaling decreasing performance

Cardio Diagnostics Holdings, Inc.'s debt to equity ratio is 0.04, which means that the company's assets are healthy financed, signaling financial stability.

Cardio Diagnostics Holdings, Inc.'s debt has decreased relative to shareholder equity from 0.10 last year to 0.04 today, signaling strengthened financials

Cardio Diagnostics Holdings, Inc. has a net cash position, so leverage is healthy.

Cardio Diagnostics Holdings, Inc.'s interest coverage ratio is -525.07, which means that the company struggles to meet interest obligations, signaling financial risk.

Cardio Diagnostics Holdings, Inc.'s profit margin has decreased (86.33%) in the last year from -24.03K% to -44.77K%, signaling decreasing performance

Cardio Diagnostics Holdings, Inc.'s short-term assets of $5.92M exceed its short-term liabilities of $604.84K

Cardio Diagnostics Holdings, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Cardio Diagnostics Holdings, Inc.'s return on equity of -82.27%, is lower than 15.00%, indicating bad performance

Cardio Diagnostics Holdings, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Cardio Diagnostics Holdings, Inc. has insufficient public price history to evaluate earnings stability.

Cardio Diagnostics Holdings, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Cardio Diagnostics Holdings, Inc. has negative free cash flow, indicating cash burn

Cardio Diagnostics Holdings, Inc.'s yearly earnings has increased -22.49% since last year from $-8.38M to $-6.50M, signaling increasing performance

Cardio Diagnostics Holdings, Inc.'s yearly revenue has decreased 57.51% since last year from $34.89K to $14.82K, signaling decreasing performance

ROIC -83.56% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Cardio Diagnostics Holdings, Inc.'s 3-year revenue CAGR of 149.89% is positive, indicating growing revenue over the past 3 years

Cardio Diagnostics Holdings, Inc. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

Cardio Diagnostics Holdings, Inc. has insufficient public price history to evaluate ROE consistency.

Cardio Diagnostics Holdings, Inc. is overvalued relative to its fair value price of 1.51 based on Discounted Cash Flow model

Cardio Diagnostics Holdings, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Cardio Diagnostics Holdings, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Cardio Diagnostics Holdings, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Cardio Diagnostics Holdings, Inc. has insufficient data to evaluate this check.

Cardio Diagnostics Holdings, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Cardio Diagnostics Holdings, Inc. has a price-to-book ratio of 0.68x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Cardio Diagnostics Holdings, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue